Optimizing initial chemotherapy for metastatic pancreatic cancer.

Related Articles

Optimizing initial chemotherapy for metastatic pancreatic cancer.

Future Oncol. 2016 May;12(9):1125-33

Authors: Mantripragada KC, Safran H

Abstract
The two combination chemotherapy regimens FOLFIRINOX and gemcitabine plus nab-paclitaxel represent major breakthroughs in the management of metastatic pancreatic cancer. Both regimens showed unprecedented survival advantage in the setting of front-line therapy. However, their application for treatment of patients in the community is challenging because of significant toxicities, thus limiting potential benefits to a narrow population of patients. Modifications to the dose intensity or schedule of those regimens improve their tolerability, while likely retaining survival advantage over single-agent chemotherapy. Newer strategies to optimize these two active regimens in advanced pancreatic cancer are being explored that can help personalize treatment to individual patients.

PMID: 26939741 [PubMed - indexed for MEDLINE]

http://ift.tt/2hs6ggT